Researchers have demonstrated for the first time that immune cells in the urine of bladder cancer patients accurately reflect those in the tumor environment.
Browsing: Disease Area > Genitourinary
NICE have approved Tecentriq® (atezolizumab), for NHS patients with advanced bladder cancer who have relapsed following prior treatment.
A novel method for diagnosing and managing prostate cancer has been developed.
A study led by researchers at The Institute of Cancer Research (London, UK) has uncovered numerous ways of targeting prostate cancer.
A novel treatment strategy could overcome drug resistance in testicular cancer, find out exclusive details in this interview with study leader Janet Shipley from the ICR (London, UK).
Discover cases studies of rare recurrences after adjuvant chemotherapy in this Editorial from Future Oncology.
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate.
Discover details of the KEYNOTE-045, which recently resulted in the recommendation for the use of pembrolizumab within the cancer drugs fund as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Pembrolizumab has become the first and only immunotherapy that NICE has recommended for urothelial carcinoma patients who have failed on platinum-containing chemotherapy.
In this research article from Future Science OA discover the implications of IL-8 in the diagnosis, aggressiveness and prognosis of prostate cancer.